Abstract： Objective： To observe the clinical effect of Jianpi Yishen Prescription combined with Fenalidone on type 2 diabetes kidney disease in the early and middle stages. Methods：A total of 60 cases of patients with type 2 diabetes kidney disease in the early and middle stages were selected as the study subjects and divided into the control group and the observation group according to the random number table method，with 30 cases in each group. The two groups were given conventional treatment to control blood glucose and blood pressure，and all patients were informed to exercise appropriately and have a reasonable diet. The control group was given the oral administration of Fenalidone Tablets based on conventional treatment，and the observation group was additionally treated with Jianpi Yishen Prescription based on the treatment of the control group. The detection results of glycated hemoglobin (HbA1c)，urea nitrogen (BUN)， estimated glomerular filtration rate (eGFR)， urinary microalbumin-to-creatinine ratio (UACR)， and blood potassium (K) were compared between the two groups. Results：After treatment，there was no significant difference being found in HbA1c，BUN，eGFR，and K between the two groups (P＞0.05). After treatment， the UACR levels in the two groups were lower than those before treatment (P＜0.05)，and the UACR levels in the observation group were lower than those in the control group (P＜0.05). Conclusion： Jianpi Yishen Prescription combined with Fenalidone can reduce urinary protein to alleviate kidney damage in the treatment of type 2 diabetes kidney disease in the early and middle stages， protect kidney function， and delay further disease progression.